Intricacies and inter-relationships between HIV disclosure and Haart

A qualitative study

Dados Bibliográficos

ID19438552
AutoresRobert Klitzman (0000-0002-6827-8063, Columbia University, autor correspondente), R L Klitzman (a HIV Center for Clinical and Behavioral Studies , New York State Psychiatric Institute and Columbia University , New York , USA), Sheri B Kirshenbaum (0000-0001-5298-9437, New York Psychoanalytic Society and Institute), Brian Dodge (0000-0003-4491-6603, New York Psychoanalytic Society and Institute), Robert H Remien (0000-0002-3963-3273, Columbia University), Anke Α Ehrhardt (0000-0003-1703-2036, New York Psychoanalytic Society and Institute), A A Ehrhardt (a HIV Center for Clinical and Behavioral Studies , New York State Psychiatric Institute and Columbia University , New York , USA), Mallory O Johnson (0000-0003-0480-2804, San Francisco AIDS Foundation), Lauren Kittel (New York Psychoanalytic Society and Institute), L E Kittel (a HIV Center for Clinical and Behavioral Studies , New York State Psychiatric Institute and Columbia University , New York , USA), Shaira Daya (New York Psychoanalytic Society and Institute), Stephen F Morin (San Francisco AIDS Foundation), J Kelly (0000-0002-3616-1768, Medical College of Wisconsin), Jeffrey A Kelly (0000-0002-5613-2809, Medical College of Wisconsin), Michael Lightfoot (0000-0001-5293-9755, UCLA Health), Mary Jane Rotheram–Borus (UCLA Health), M J Rotheram-Borus (d Center for Community Health , UCLA Neuropsychiatric Institute Los Angeles , California , USA)
Ano2004
Volume16
Fascículo5
Páginas628-640
Data de publicação2004-07-01
Peer ReviewedSim
Open AccessNão
TipoARTICLE
PeriódicoAIDS Care (JOURNAL)
Identificadores do periódicoISSN: 0954-0121 • E-ISSN: 1360-0451
EditoraInforma UK Limited (PUBLISHER • GB)
DOI10.1080/09540120410001716423
PMID15223532
OpenAlexW2019875816
IdiomaEN
Citações recebidas48
Referências citadas31

This study aimed to understand whether and how highly active antiretroviral treatment (HAART) affects views and patterns of disclosure and how disclosure interacts with treatment decisions. One hundred and fifty-two HIV-positive adults (52 MSM, 56 women and 44 IDU men) from four US cities participated in two to three-hour, semi-structured interviews in 1998-99. Results indicate that HAART interacts with and shapes HIV disclosure issues in several ways. Medications may 'out' people living with HIV. Thus, in different settings (e.g. work, prisons, drug rehabs and public situations), some try to hide medications or modify dosing schedules, which can contribute to non-adherence, and affect sexual behaviours. Disclosure of HIV and/or HAART may also result in antagonism from others who hold negative attitudes and beliefs about HAART, potentially impeding adherence. Observable side effects of medications can also 'out' individuals. Conversely, medications may improve appearance, delaying or impeding disclosure. Some wait until they are on HAART and look 'well' before disclosing; some who look healthy as a result of medication deny being HIV-positive. Alternatively, HIV disclosure can lead to support that facilitates initiation of, and adherence to, treatment. HIV disclosure and adherence can shape one another in critical ways. Yet these interactions have been under-studied and need to be further examined. Interventions and studies concerning each of these domains have generally been separate, but need to be integrated, and the importance of relationships between these two areas needs to be recognized

Antiretroviral therapy · Dosing · Family medicine · Full disclosure · Psychiatry · Psychological intervention · Qualitative research · Viral load · Clinical Psychology · HIV, Drug Use, Sexual Risk · HIV/AIDS Research and Interventions · LGBTQ Health, Identity, and Policy · Medicine · Psychology · Pharmacology